Actively Recruiting

Phase 1
Phase 2
Age: 50Years +
All Genders
NCT06141460

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Led by Shanghai Refreshgene Technology Co., Ltd. · Updated on 2024-11-14

48

Participants Needed

1

Research Sites

368 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration

CONDITIONS

Official Title

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing and able to follow study procedures
  • Age 50 years or older
  • Clinically diagnosed with choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration
  • Best corrected visual acuity (BCVA) of the study eye between 5 and 73 letters (Snellen 20/800 to 20/40)
  • BCVA of the other eye 19 letters or better (Snellen 20/400)
  • Responding to anti-vascular endothelial growth factor (anti-VEGF) treatment
Not Eligible

You will not qualify if you...

  • Presence of other eye diseases besides neovascular age-related macular degeneration in the study eye that could affect treatment or study results
  • CNV or macular edema in the study eye caused by conditions other than age-related macular degeneration
  • Uncontrolled glaucoma
  • Uncontrolled hypertension despite medication
  • Pregnant or lactating women or individuals with reproductive potential unwilling to use effective contraception during the study period

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tianjin Medical University Eye Hospital

Tianjin, Tianjin Municipality, China, 300384

Actively Recruiting

Loading map...

Research Team

X

Xiaorong Li, Master

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here